![]() | |
Clinical data | |
---|---|
Other names | RG-7795; ANA773; ANA-773 |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C12H14N4O5S |
Molar mass | 326.33 g·mol−1 |
3D model ( JSmol) | |
| |
|
RG7795 (previously ANA773) is an antiviral drug candidate that as of 2015 had been in Phase II trials in hepatitis B. [1] It is an orally-available prodrug of isatoribine, [2] that was under development by Anadys Pharmaceuticals when it was acquired by Roche in 2011. [3] Its active metabolite is an agonist of TLR7; activation of TLR7 causes secretion of endogenous type 1 interferons, which have antiviral activity. [2]
As of 2021, development of RG7795 appears to be discontinued. [4]
{{
cite journal}}
: CS1 maint: multiple names: authors list (
link)
![]() | |
Clinical data | |
---|---|
Other names | RG-7795; ANA773; ANA-773 |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C12H14N4O5S |
Molar mass | 326.33 g·mol−1 |
3D model ( JSmol) | |
| |
|
RG7795 (previously ANA773) is an antiviral drug candidate that as of 2015 had been in Phase II trials in hepatitis B. [1] It is an orally-available prodrug of isatoribine, [2] that was under development by Anadys Pharmaceuticals when it was acquired by Roche in 2011. [3] Its active metabolite is an agonist of TLR7; activation of TLR7 causes secretion of endogenous type 1 interferons, which have antiviral activity. [2]
As of 2021, development of RG7795 appears to be discontinued. [4]
{{
cite journal}}
: CS1 maint: multiple names: authors list (
link)